Brain health: time matters in multiple sclerosis presents consensus recommendations on diagnosis, therapeutic strategies and improving access to treatment in MS. Its core recommendation is that the goal of treating MS should be to preserve tissue in the central nervous system and maximize lifelong brain health by reducing disease activity. The report calls for major policy changes aimed at achieving the best possible outcomes for people with MS and those who care for them.

Brain health: time matters in multiple sclerosis was developed by an international multidisciplinary group of experts under the chairmanship of Professor Gavin Giovannoni and has been endorsed by a number of professional associations and advocacy groups.

Why time matters

Learn about the latest advances in understanding MS

Learn more

Executive summary

Find out about the vision behind the report and campaign – in a nutshell

Find out more

Policy recommendations

Read the consensus recommendations from the report

Read now


The organizations listed below endorse the recommendations made in Brain health: time matters in multiple sclerosis.

Accelerated Cure project
MS Australia
MS Research Australia
European Brain Council
International society of Neuroimmunulogy
MS Ireland
Multiple Sclerosis Association of America
Multiple Sclerosis International Federation
Multiple Sclerosis Society
Multiple Sclerosis Society of Canada
Multiple Sclerosis Society of Norway [Multippel Sklerose Forbundet]
Multiple Sclerosis Trust
National MS Society
Neuro Sweden
Unie Roska
The Work Foundation

The MS Trust warmly welcomes this important report. It is a timely, well-considered and mature exploration of the clinical, service and policy issues that impact the treatment of people with relapsing forms of multiple sclerosis

Amy Bowen, Multiple Sclerosis Trust

This is an easy to read, beautifully illustrated, well-updated document.

Takahiko Saida, Pan-Asian Committee for Treatment and Research in Multiple Sclerosis

This report is an outstanding milestone to guide clinicians to approach MS appropriately, according to the most recent scientific evidence.

Marco Aurélio Lana-Peixoto, Brazilian Committee for Treatment and Research in Multiple Sclerosis